Literature DB >> 24463035

Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects.

Christina E Khodr1, Amanda Becerra1, Ye Han1, Martha C Bohn2.   

Abstract

BACKGROUND: Alpha-synuclein (SNCA) downregulation shows therapeutic potential for synucleinopathies, including Parkinson's disease (PD). Previously we showed that human (h)SNCA gene silencing using a short hairpin (sh)RNA in rat substantia nigra (SN) protects against a hSNCA-induced forelimb deficit, but not dopamine (DA) neuron loss. Furthermore, the shRNA increases cell death in vitro, but the same target sequence embedded in a microRNA30 transcript (mir30-hSNCA) does not.
OBJECTIVE: Examine hSNCA gene silencing using mir30-hSNCA in vivo.
METHODS: Rats were stereotaxically injected into one SN with adeno-associated virus serotype 2/8 (AAV)-hSNCA, AAV-hSNCA plus AAV-mir30-SNCA or AAV-hSNCA plus a control non-silencing mir30-embedded siRNA and DA neuron markers and associated behavior were examined.
RESULTS: AAV2/8-mediated SN hSNCA expression induces a forelimb deficit and tyrosine hydroxylase-immunoreactive (TH-IR) neuron loss. hSNCA gene silencing using mir30-hSNCA protects against this forelimb deficit at 2 m and ameliorates TH-IR neuron loss. Striatal (ST) TH-IR fiber density and DA markers, assessed by western blot, are unaffected by AAV-hSNCA alone. Co-expression of either silencing vector reduces ST TH-IR fibers, panTH in SN and Ser40 phosphorylated TH in SN and ST, but does not affect vesicular monoamine transporter-2. However, hSNCA gene silencing promotes partial TH-IR fiber recovery by 2 m. Co-expression of either silencing vector also induces SN inflammation, although some recovery was observed by 2 m in hSNCA-silenced SN.
CONCLUSION: hSNCA gene silencing with AAV-mir30-hSNCA has positive effects on forelimb behavior and SN DA neurons, which are compromised by inflammation and reduced TH expression, suggesting that AAV2/8-mir30-hSNCA-mediated gene silencing, although promising in vitro, is not a candidate for therapeutic translation for PD.
Copyright © 2014 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Gene therapy; Neurodegeneration; RNAi; Substantia nigra; Tyrosine hydroxylase

Mesh:

Substances:

Year:  2014        PMID: 24463035      PMCID: PMC3974902          DOI: 10.1016/j.brainres.2014.01.010

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  34 in total

1.  Overexpression of exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs.

Authors:  Rui Yi; Brian P Doehle; Yi Qin; Ian G Macara; Bryan R Cullen
Journal:  RNA       Date:  2004-12-21       Impact factor: 4.942

2.  Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo.

Authors:  Ryan L Boudreau; Inês Martins; Beverly L Davidson
Journal:  Mol Ther       Date:  2008-11-11       Impact factor: 11.454

3.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

4.  Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.

Authors:  Eric K Richfield; Mona J Thiruchelvam; Deborah A Cory-Slechta; Charles Wuertzer; Raul R Gainetdinov; Marc G Caron; Donato A Di Monte; Howard J Federoff
Journal:  Exp Neurol       Date:  2002-05       Impact factor: 5.330

5.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.

Authors:  E Masliah; E Rockenstein; I Veinbergs; M Mallory; M Hashimoto; A Takeda; Y Sagara; A Sisk; L Mucke
Journal:  Science       Date:  2000-02-18       Impact factor: 47.728

6.  A microRNA embedded AAV α-synuclein gene silencing vector for dopaminergic neurons.

Authors:  Ye Han; Christina E Khodr; Mohan K Sapru; Jyothi Pedapati; Martha C Bohn
Journal:  Brain Res       Date:  2011-02-19       Impact factor: 3.252

7.  Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs.

Authors:  Ryan L Boudreau; Alex Mas Monteys; Beverly L Davidson
Journal:  RNA       Date:  2008-08-12       Impact factor: 4.942

Review 8.  Clinical overview of the synucleinopathies.

Authors:  Maria J Martí; Eduardo Tolosa; Jaume Campdelacreu
Journal:  Mov Disord       Date:  2003-09       Impact factor: 10.338

9.  The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.

Authors:  Oleg S Gorbatyuk; Shoudong Li; Layla F Sullivan; Weijun Chen; Galina Kondrikova; Fredric P Manfredsson; Ronald J Mandel; Nicholas Muzyczka
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-04       Impact factor: 11.205

10.  Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC.

Authors:  Daniela Castanotto; Kumi Sakurai; Robert Lingeman; Haitang Li; Louise Shively; Lars Aagaard; Harris Soifer; Anne Gatignol; Arthur Riggs; John J Rossi
Journal:  Nucleic Acids Res       Date:  2007-07-26       Impact factor: 16.971

View more
  25 in total

Review 1.  Gene therapy targeting mitochondrial pathway in Parkinson's disease.

Authors:  Chi-Jing Choong; Hideki Mochizuki
Journal:  J Neural Transm (Vienna)       Date:  2016-09-16       Impact factor: 3.575

Review 2.  Role of viruses, prions and miRNA in neurodegenerative disorders and dementia.

Authors:  Sayed Sartaj Sohrab; Mohd Suhail; Ashraf Ali; Mohammad Amjad Kamal; Azamal Husen; Fahim Ahmad; Esam Ibraheem Azhar; Nigel H Greig
Journal:  Virusdisease       Date:  2018-09-29

3.  Investigation of RNA Synthesis Using 5-Bromouridine Labelling and Immunoprecipitation.

Authors:  Rikke H Kofoed; Cristine Betzer; Søren Lykke-Andersen; Ewa Molska; Poul H Jensen
Journal:  J Vis Exp       Date:  2018-05-03       Impact factor: 1.355

4.  Noninvasive delivery of an α-synuclein gene silencing vector with magnetic resonance-guided focused ultrasound.

Authors:  Kristiana Xhima; Fadl Nabbouh; Kullervo Hynynen; Isabelle Aubert; Anurag Tandon
Journal:  Mov Disord       Date:  2018-09-28       Impact factor: 10.338

Review 5.  Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations.

Authors:  Benjamin Dehay; Mathieu Bourdenx; Philippe Gorry; Serge Przedborski; Miquel Vila; Stephane Hunot; Andrew Singleton; C Warren Olanow; Kalpana M Merchant; Erwan Bezard; Gregory A Petsko; Wassilios G Meissner
Journal:  Lancet Neurol       Date:  2015-06-03       Impact factor: 44.182

6.  Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease.

Authors:  Brian Spencer; Ivy Trinh; Edward Rockenstein; Michael Mante; Jazmin Florio; Anthony Adame; Omar M A El-Agnaf; Changyoun Kim; Eliezer Masliah; Robert A Rissman
Journal:  Neurobiol Dis       Date:  2019-03-05       Impact factor: 5.996

Review 7.  Nucleic Acid-Based Therapeutics for Parkinson's Disease.

Authors:  Masayuki Nakamori; Eunsung Junn; Hideki Mochizuki; M Maral Mouradian
Journal:  Neurotherapeutics       Date:  2019-04       Impact factor: 7.620

Review 8.  MicroRNA-22: a Novel and Potent Biological Therapeutics in Neurological Disorders.

Authors:  Seyed Hamidreza Rastegar-Moghaddam; Alireza Ebrahimzadeh-Bideskan; Sara Shahba; Amir Mohammad Malvandi; Abbas Mohammadipour
Journal:  Mol Neurobiol       Date:  2022-02-14       Impact factor: 5.590

Review 9.  Nanotechnology-Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID-19 Vaccines.

Authors:  Chiara Rinoldi; Seyed Shahrooz Zargarian; Pawel Nakielski; Xiaoran Li; Anna Liguori; Francesca Petronella; Dario Presutti; Qiusheng Wang; Marco Costantini; Luciano De Sio; Chiara Gualandi; Bin Ding; Filippo Pierini
Journal:  Small Methods       Date:  2021-07-28

Review 10.  Role of MicroRNAs, Aptamers in Neuroinflammation and Neurodegenerative Disorders.

Authors:  Islauddin Khan; Kumari Preeti; Valencia Fernandes; Dharmendra Kumar Khatri; Shashi Bala Singh
Journal:  Cell Mol Neurobiol       Date:  2021-05-01       Impact factor: 4.231

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.